
CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about the important role that patient support networks play for those with cancer and the challenge of separating patients from their loved ones during the COVID-19 pandemic.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Published: October 8th 2021 | Updated:

Published: October 13th 2021 | Updated: